News

United Therapeutics upgraded to Neutral at BofA following selloff
As previously reported, BofA analyst Jason Gerberry upgraded United Therapeutics (UTHR) to Neutral from Underperform with an unchanged price ...
United Therapeutics upgraded to Neutral from Underperform at BofA
BofA upgraded United Therapeutics (UTHR) to Neutral from Underperform with a $314 price target Stay Ahead of the Market: Discover ...
TRYVIO/JERAYGO Positioned To Redefine Treatment Of Resistant Hypertension Delveinsight
TRYVIO (aprocitentan) in the US and JERAYGO in Europe present significant market potential as novel therapies for patients with hypertension ...
DelveInsight Business Research, LLP: TRYVIO/JERAYGO Positioned to Redefine Treatment of Resistant Hypertension | DelveInsight
TRYVIO (aprocitentan) in the US and JERAYGO in Europe present significant market potential as novel therapies for patients with hypertension inadequately controlled by existing treatments. TRYVIO ...
Newsday6d
Behind the story of the decades-long journey of xenotransplantation
Probably the most famous of them was Baby Faye in 1984, who lived for 21 days with a baboon’s heart. They didn’t work because ...